

Supplementary Table 1 Adverse events reported in randomized controlled trials for use of hydroxychloroquine in COVID-19 patients

	RCT	Sample (n)	Adverse events n (%)																			
			Total		Gastro		Neuro		Skin		Cardio		Respiratory		Fatigue		Liver function		Renal		Other	
			Placebo	HCQ	Placebo	HCQ	Placebo	HCQ	Placebo	HCQ	Placebo	HCQ	Placebo	HCQ	Placebo	HCQ	Placebo	HCQ	Placebo	HCQ	Placebo	HCQ
1	Tang et al. (2020)	150	7(9)	21(30)	1(1)	13(18.5)	-	1(1)	1(1)	1(1)	-	3(4)	-	2(2.5)	-	1(1)	2(2.5)	2(2.5)	1(1)	1(1)	2(2.5)	5(7)
2	Abella et al. (2020)	130	17(26)	29(45)	16(24.6)	40(61.5)	4(6)	1(2)	1(2)	4(6)	1(2)	1(2)	1(2)	-	-	2(3)	-	-	-	-	-	-
3	Mitja et al. (2020)	353	18(9.8)	122(72.2)	7(3.8)	148(88.1)	3(1.6)	75(44.3)	-	11(6.5)	-	1(0.6)	-	2(1.2)	-	-	-	-	-	1(0.6)	14(7.6)	44(26)
4	Boulware et al. (2020)	700	59(16.8)	140(40.1)	42(12)	161(46.1)	24(6.8)	43(12.3)	2(0.6)	4(1.1)	-	-	-	-	1(0.3)	1(0.3)	-	-	-	-	3(0.8)	6(1.7)
5	Skipper et al. (2020)	423	46(22)	92(43)	46(22)	116(54.7)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
6	Cavalcanti et al. (2020)	665	40(22.6)	67(33.7)	2(1.1)	9(4.5)	-	-	-	1(0.5)	2(1)	6(3)	-	1(0.5)	-	-	8(4)	22(11)	-	-	48(24)	50(25)
7	Chen et al. (2020)	30	3(20)	4(27)	-	2(13)	-	-	-	-	-	-	-	-	-	1(7)	1(7)	1(7)	1(7)	-	1(7)	-
8	Rosenberg et al. (2020)	1438	171(77.3)	255(94)	16(7.2)	22(17)	-	-	-	-	155(70.1)	233(86)	-	-	2(0.5)	4(1)	-	-	-	-	6(2.7)	9(3.3)
9	Mahevas et al. (2020)	181	-	8(9.5)	-	-	-	-	-	-	-	8(9.5)	-	-	-	-	-	-	-	-	-	-
10	Barnabas et al. (2020)	829	46(10.9)	66(16.2)	17(4)	39(9.5)	24(5.7)	16(4)	8(1.9)	11(2.7)	-	-	-	-	-	-	-	-	-	-	6(1.4)	4(1)
11	Chen et al. (2020a)	33	3(20)	9(47.3)	2(13.3)	3(15.8)	-	6(31.6)	-	-	-	-	-	-	-	-	1(0.6)	-	-	-	-	-
12	Chen et al. (2020b)	62	-	2(6.4)	-	-	-	1(3.2)	-	1(3.2)	-	-	-	-	-	-	-	-	-	-	-	-
13	Dubee et al. (2020)	244	61(50.8)	70(56.5)	11(9.2)	14(11.3)	14(11.6)	12(9.7)	7(5.8)	10(8.1)	7(5.8)	6(4.8)	-	-	-	-	3(2.5)	8(6.5)	-	4(3.2)	7(5.8)	8(6.5)
14	Kelly et al. (2020)	134	22(42)	35(42)	-	-	-	-	-	-	1(2)	11(3.4)	-	-	-	-	43(52)	53(65)	-	-	-	-
15	Mitja et al.	2497	77(5.9)	671(55)	33(2.5)	510(44)	32(2.6)	260(21)	-	-	1(0.1)	5(0.4)	-	-	-	-	-	-	-	-	10(0.4)	103(8.4)

5	(2020))	6.1))	2.6)	5)	21.7))								8)	.6)		
16	Self et al. (2020)	479	32(13.5)	44(18.2)	5(2.1)	6(2.5)	7(3)	6(2.5)	2(0.8)	1(0.4)	15(63)	9(37)	2(0.8)	7(2.9)	-	-	5(2.1)	13(5.4)	-	1(0.4)	3(1.2)	7(2.9)
17	Ulrich et al. (2020)	128	36(59)	38(56.7)	10(16.4)	17(25.4)	2(3.3)	1(1.5)	4(6.6)	1(1.5)	-	-	-	-	-	-	-	-	-	-	-	-
18	Grau-Pujol et al. (2020)	269	42(33.1)	53(37.3)	42(33.1)	88(62)	24(18.9)	28(19.7)	4(3.1)	7(5)	2(1.6)	2(1.4)	20(15.7)	10(7)	-	-	-	-	-	-	31(24.4)	30(21.1)
19	Lyngbakken et al. (2020)	53	6(23.1)	5(18.5)	-	-	-	-	-	-	-	-	5(19.2)	5(18.5)	-	-	-	-	1(3.8)	-	-	-
20	Rajasingham et al. (2020)	1405	100(21)	316(33.7)	92(19.6)	313(33.4)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
21	Chen et al. (2020)	48	2(16.7)	9(50)	2(16.7)	6(33.3)	-	-	-	-	-	-	-	-	-	1(5.6)	-	2(11.1)	-	-	-	-

1. Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. *BMJ*. 2020;369:m1849.
2. Abella BS, Jolkovsky EL, Biney BT, et al. Efficacy and safety of hydroxychloroquine vs placebo for pre-exposure SARS-CoV-2 prophylaxis among health care workers: A randomized clinical trial: A randomized clinical trial. *JAMA Intern Med*. 2021;181(2):195-202.
3. Mitjà O, Corbacho-Monné M, Ubals M, et al. Hydroxychloroquine for early treatment of adults with mild Covid-19: A randomized-controlled trial. *Clin Infect Dis*. Published online 2020. doi:10.1093/cid/ciaa1009
4. Boulware DR, Pullen MF, Bangdiwala AS, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. *N Engl J Med*. 2020;383(6):517-525.
5. Skipper CP, Pastick KA, Engen NW, et al. Hydroxychloroquine in nonhospitalized adults with early COVID-19: A randomized trial: A randomized trial. *Ann Intern Med*. 2020;173(8):623-631.
6. Cavalcanti AB, Zampieri FG, Rosa RG, et al. Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. *N Engl J Med*. 2020;383(21):2041-2052.
7. Chen J, Liu D, Liu L, et al. A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19. *Zhejiang Da Xue Xue Bao Yi Xue Ban*. 2020;49(2):215-219.
8. Rosenberg ES, Dufort EM, Udo T, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state. *JAMA*. 2020;323(24):2493-2502.
9. Mahevas M, Tran V-T, Roumier M, et al. No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial. *bioRxiv*. Published online 2020. doi:10.1101/2020.04.10.20060699
10. Barnabas RV, Brown ER, Bershteyn A, et al. Hydroxychloroquine as postexposure prophylaxis to prevent severe acute respiratory syndrome Coronavirus 2 infection: A randomized trial: A randomized trial. *Ann Intern Med*. 2021;174(3):344-352.
11. Chen C-P, Lin Y-C, Chen T-C, et al. A multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate coronavirus disease 2019 (COVID-19). *PLoS One*. 2020;15(12):e0242763.

- 12.Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. bioRxiv. Published online 2020. doi:10.1101/2020.03.22.20040758
- 13.Dubée V, Roy P-M, Vielle B, et al. A placebo-controlled double blind trial of hydroxychloroquine in mild-to-moderate COVID-19. bioRxiv. Published online 2020. doi:10.1101/2020.10.19.20214940
- 14.Kelly M, O'Connor R, Townsend L, et al. Clinical outcomes and adverse events in patients hospitalised with COVID-19, treated with off-label hydroxychloroquine and azithromycin. *Br J Clin Pharmacol*. 2021;87(3):1150-1154.
- 15.Mitjà O, Corbacho-Monné M, Ubals M, et al. A cluster-randomized trial of hydroxychloroquine for prevention of Covid-19. *N Engl J Med*. 2021;384(5):417-427.
- 16.Self WH, Semler MW, Leither LM, et al. Effect of hydroxychloroquine on clinical status at 14 days in hospitalized patients with COVID-19: A randomized clinical trial: A randomized clinical trial. *JAMA*. 2020;324(21):2165-2176.
- 17.Ulrich RJ, Troxel AB, Carmody E, et al. Treating COVID-19 with hydroxychloroquine (TEACH): A multicenter, double-blind randomized controlled trial in hospitalized patients. *Open Forum Infect Dis*. 2020;7(10):ofaa446.
- 18.Grau-Pujol B, Camprubí D, Marti-Soler H, et al. Pre-exposure prophylaxis with hydroxychloroquine for COVID-19: initial results of a double-blind, placebo-controlled randomized clinical trial. *Research Square*. Published online 2020. doi:10.21203/rs.3.rs-72132/v1
- 19.Lyngbakken MN, Berdal J-E, Eskesen A, et al. A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics. *Nat Commun*. 2020;11(1):5284.
- 20.Rajasingham R, Bangdiwala AS, Nicol MR, et al. Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial. medRxiv. Published online 2020. doi:10.1101/2020.09.18.20197327
- 21.Chen L, Zhang Z-Y, Fu J-G, et al. Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study. bioRxiv. Published online 2020. doi:10.1101/2020.06.19.20136093